Cumberland Pharmaceuticals (CPIX) to Post Earnings on Tuesday

Cumberland Pharmaceuticals (NASDAQ:CPIX) is expected to be releasing its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect the company to post earnings of ($0.13) per share and revenue of $8.5030 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its quarterly earnings data on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) EPS for the quarter, meeting analysts’ consensus estimates of ($0.13). The firm had revenue of $9.13 million for the quarter, compared to analyst estimates of $8.50 million. Cumberland Pharmaceuticals had a negative return on equity of 12.01% and a negative net margin of 17.60%.

Cumberland Pharmaceuticals Stock Performance

CPIX stock opened at $6.68 on Monday. The business has a fifty day moving average of $6.29 and a 200-day moving average of $4.72. The company has a market cap of $100.07 million, a P/E ratio of -13.63 and a beta of 0.08. Cumberland Pharmaceuticals has a twelve month low of $1.85 and a twelve month high of $8.09. The company has a quick ratio of 0.79, a current ratio of 0.95 and a debt-to-equity ratio of 0.25.

Cumberland Pharmaceuticals Dividend Announcement

The firm also recently announced a dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, July 23rd were given a dividend of $1.50 per share.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Wednesday, June 24th. Wall Street Zen cut shares of Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. XTX Topco Ltd bought a new stake in shares of Cumberland Pharmaceuticals in the 2nd quarter valued at $34,000. Two Sigma Investments LP increased its holdings in shares of Cumberland Pharmaceuticals by 16.5% in the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock worth $117,000 after acquiring an additional 5,326 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Cumberland Pharmaceuticals during the fourth quarter worth about $192,000. Geode Capital Management LLC lifted its holdings in shares of Cumberland Pharmaceuticals by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock valued at $427,000 after purchasing an additional 5,653 shares in the last quarter. Finally, Bridgeway Capital Management LLC grew its position in shares of Cumberland Pharmaceuticals by 2.3% in the 2nd quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock valued at $631,000 after purchasing an additional 4,200 shares during the period. Institutional investors and hedge funds own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.